One in ten British adults used or interested in GLP-1 medications for weight loss owenhaskins Jan 8 4 min read In 2025, approximately 4.9 million British adults almost one in ten are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss
Southend Pharmacy is a 503A facility that requires a valid patient-specific prescription from a licensed healthcare provider
Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor
Luxury Custom Box creates brilliant packaging to customize, store and ship any product or valuable item
Complementing these findings, a separate trial assessing the efficacy of exenatide for alcohol use disorder also showed no significant difference in heavy drinking days overall
PubMed Central, Engstrm, Karin Schlwicke, et al